Charles Schwab Investment Management Inc Travere Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 555,472 shares of TVTX stock, worth $4.57 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
555,472
Previous 539,487
2.96%
Holding current value
$4.57 Million
Previous $4.85 Million
11.69%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$64.1 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$61.7 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$60.6 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$54.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$51.5 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $528M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...